Indaptus Therapeutics Inc (INDP) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
Indaptus Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Indaptus Therapeutics Inc 's ROA in the second quarter of 2026?
Indaptus Therapeutics Inc recorded a cumulative net loss of $-15 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -132.07%.
However, within the Healthcare sector 857 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4560, from total ROA ranking in the first quarter of 2026 at 5270.
Indaptus Therapeutics Inc. a leader in immunotherapy innovation, has made significant strides with its cutting-edge Decoy platform, which focuses on combating cancer through novel immunotherapeutic approaches. Recently, the company published preclinical data in the peer-reviewed journal Frontiers in Immunology , shedding light on the single-agent anti-tumor activity of their Decoy platform. This data also underscores the potential for combination therapies that include non-steroidal anti-inflammatory drugs (NSAIDs), anti-PD1 checkpoint inhibitors, low-dose chemotherapy (LDC), and targeted antibody therapies. These findings could herald a transformative shift in how immunotherapy is approached and applied in clinical settings. Key Findings from Recent Research:1. Decoy Platform Efficacy: - The Decoy platform has demonstrated notable anti-tumor activity as a single agent. - The effectiveness of combination therapies, particularly when paired with established treatments like NSAIDs and anti-PD1 therapies, has shown potential for comprehensive tumor eradication.
:Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company renowned for developing groundbreaking treatments for cancer and viral infections, recently disclosed promising new safety data pertaining to its Decoy20 clinical program. Driven by these encouraging results, the company has commenced an expanded patient enrollment initiative for weekly dosing across two distinct dose regimens. This article delves into the salient aspects of these advancements, focusing on their potential implications for cancer treatment, viral infection therapy, and personalized medicine. Indaptus Therapeutics has a proven track record in the field of biologics, focusing primarily on developing novel and effective treatments for some of the most challenging diseases, such as cancer and viral infections. The company s proprietary platform leverages advanced molecular technology to create targeted therapies that are both potent and safe. The Decoy20 clinical program is one such initiative that the company has recently reported substantial progress on, particularly in terms of safety data and patient enrollment.
Indaptus Therapeutics, Inc. Secures $3.0 Million in Funding for Groundbreaking Cancer and Viral Infection Treatments August 7, 2024 - Indaptus Therapeutics, Inc. (Nasdaq: INDP), a pioneering clinical stage biotechnology company, announced today the successful completion of a $3.0 million registered direct offering and concurrent private placement. This funding milestone underscores Indaptus commitment to revolutionizing cancer and viral infection treatments through innovative therapies. Under securities purchase agreements, Indaptus has secured investments from various investors, including one of its own officers, totaling 1,643,837 shares of common stock. Additionally, the company has agreed to issue and sell unregistered warrants, granting the opportunity to purchase up to 1,643,837 additional shares of common stock. The combined purchase price for each share of common stock and associated warrants is set at $1.825. These warrants will become exercisable immediately upon issuance, with an exercise price of $1.70 per share, and will remain valid for a period of five years. The closing of the offering is anticipated to occur on or around August 8, 2024, pending the fulfillment of customary closing conditions. This promising injection of capital will allow Indaptus to accelerate its groundbreaking research and development initiatives, ultimately advancing the development of highly effective cancer and viral infection treatment options.
Introduction Indaptus Therapeutics Inc, a leading biopharmaceutical company in the healthcare sector, is set to present the initial clinical data on their lead product candidate, Decoy20, at the upcoming STING and TLR-Targeted Therapies Summit. Dr. Newman, Chief Scientific Officer at Indaptus, will shed light on the latest findings that further validate the company s Pulse-Prime hypothesis. This announcement comes at a pivotal time for Indaptus, as the stock recently experienced a significant surge in value. Indaptus Stock Performance and Financials In May 2024, Indaptus Therapeutics Inc witnessed a remarkable 15.49% increase in its stock prices. This surge in value reflects a growing investor confidence in the company s potential, likely fueled by anticipated positive outcomes from the clinical trials of their flagship product candidate, Decoy20.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
